AI-generated summary
In this prospective study of 147 patients with oral potentially malignant disorders, the authors report treating them with surface illumination photodynamic therapy using 5-ALA or mTHPC as the photosensitizer. Over a mean follow-up of 7.3 years, 119 of 147 patients (81%) reached complete response, and the authors conclude the approach offers an effective alternative treatment. The study is uncontrolled, and the authors describe recurrence and malignant transformation in some patients, mainly in erythroplakias and non-homogenous leukoplakias.
- Participants
- 147
- Who or what was studied
- Patients with oral potentially malignant disorders (homogenous and non-homogenous leukoplakias and erythroplakias), average age 53 years
- Limits stated in the abstract
- The study is a single prospective cohort without a control group, and the abstract reports recurrence in about 11.6% and malignant transformation in 7.5% of patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.